Menopausal vaginal syndrome (MVS): a new non hormonal topical therapy

ABSTRACT

Objective. The aim of this clinic retrospective study was to assess the regression of Menopausal Vaginal Syndrome following topical therapy with 2 g vaginal device in ovuli based on “DuoLact-EvoGold”, whose active ingredients are: “A. Lactoferrin, Lactobacillus casei and acidophilus, FOS, and GOS and B. Natural vitamin E and Extra‑virgin Olive Oil”.

Materials and Methods. The treatment consisted of one ovule 2 g “Duolact-Evogold” administered each evening for 10 consecutive days, followed by a 15‑day treatment suspension, and then a maintenance phase of 5 days. Symptom severity was evaluated using the Verbal Numerical Scale, while vaginoscopic findings and vaginal pH were assessed using the Visual Analogue Scale and Visual Colorimetric Scale. The “Grading classification” uses a score from 0 to 3. Sexual satisfaction was measured by the “Female Sexual Function Index”.

Results. At baseline (T0), the most severe symptoms in patients with Menopausal Vaginal Syndrome were vaginal dryness and dyspareunia (each present in 47 patients; 78.3 %) and post‑coital spotting (27 patients; 45 %). Complete regression at T3 was observed for vaginal dryness and dyspareunia in 47 (78.3 %) and 45 (75 %) patients, respectively; complete absence of post‑coital spotting was noted in 40 patients (66.7 %). Spontaneous vaginal pain regressed completely.

Conclusions. Local therapy with “DuoLac-EvoGold” appears promising for the treatment of MVS, given its high rate of complete symptom regression.

Key words

Menopause; non hormonal topical therapy; vagina; menopausal vaginal syndrome; topical therapy.